Results 31 to 40 of about 104,308 (265)

From mice to humans—divergent strategies for intestinal homeostasis and regeneration

open access: yesFEBS Letters, EarlyView.
Recent advances such as organoid genome editing, xenotransplantation, imaging, and whole‐genome sequencing have enabled direct studies of human intestinal stem cells (ISCs). These studies reveal species‐specific features, including slower ISC proliferation, distinct injury responses, slower somatic mutation accumulation in humans, and an inverse ...
Keiko Ishikawa   +2 more
wiley   +1 more source

Evidence for proton-pump inhibitor (PPI)-associated dysbiosis in metabolically unhealthy obesity

open access: yesFrontiers in Endocrinology, 2023
Obesity adversely impacts millions of American adults by predisposing them to significant health risks and further complications. Obesity is differentiated into two groups: metabolically healthy and metabolically unhealthy.
Melissa A. Burmeister   +3 more
doaj   +1 more source

Design and analysis strategies for robust microbiome ageing research

open access: yesFEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik   +5 more
wiley   +1 more source

Unraveling 4‐Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw   +5 more
wiley   +1 more source

Sodium oligomannate modulates the gut-brain axis to alleviate post-stroke cognitive impairment by restoring butyrate metabolism

open access: yesMicrobiome
Background Post-stroke cognitive impairment (PSCI) affects up to half of stroke survivors, severely impacting their quality of life. Despite its prevalence, the pathogenesis of PSCI remains poorly understood, and no specific pharmacological treatments ...
Yueran Ren   +10 more
doaj   +1 more source

The impact of butyrate on glycemic control in animals and humans: a comprehensive semi-systemic review

open access: yesFrontiers in Nutrition
The gut microbiome has been identified as a significant factor in host metabolism, playing a key role in the etiology of obesity, type 2 diabetes and cardiometabolic risk. Butyrate, produced by the gut microbiome from indigestible carbohydrates, has been
Nouhaila Hamari   +2 more
doaj   +1 more source

Sodium Butyrate Ameliorates Gut Microbiota Dysbiosis in Lupus-Like Mice

open access: yesFrontiers in Nutrition, 2020
Gut microbiota has a strong influence on the onset and development of systemic lupus erythematosus (SLE), and several studies have demonstrated the effectiveness of microbiota-derived butyrate to ameliorate SLE.
Hanchang He   +7 more
doaj   +1 more source

A Modular Liver–Microbial Microfluidic Platform to Evaluate Therapeutic and Adverse Effects of Microbial Metabolites

open access: yesAdvanced Healthcare Materials, EarlyView.
This study introduces a modular microfluidic platform that connects liver cells with live microbes to mimic key aspects of the gut–liver interaction in steatosis. Using this system, both microbial metabolites and live bacteria significantly reduced fat accumulation in liver cells, but live microbes triggered inflammation and broader metabolic changes ...
Hsih‐Yin Tan   +7 more
wiley   +1 more source

Urban sports fields support higher levels of soil butyrate and butyrate‐producing bacteria than urban nature parks

open access: yesEcology and Evolution
Butyrate‐producing bacteria colonise the gut of humans and non‐human animals, where they produce butyrate, a short‐chain fatty acid with known health benefits.
Joel E. Brame   +6 more
doaj   +1 more source

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

open access: yesAdvanced Materials, EarlyView.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy